Fr. 189.00

Death Receptors in Cancer Therapy

Inglese · Copertina rigida

Spedizione di solito entro 6 a 7 settimane

Descrizione

Ulteriori informazioni

An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes. The authors focus on the extrinsic system of death receptors, their regulation and function, and their abnormalities in cancer. Topics of particular interest include resistance to apoptosis, TRAIL signaling, death receptors in embryonic development, mechanisms of caspase activation, and death receptor mutations in cancer. Additional chapters address death signaling in melanoma, synthetic retinoids and death receptors, the role of p53 in death receptor regulation, immune suppression of cancer, and combination therapy with death ligands.

Sommario

Mammalian Cell Death Pathways.- Resistance to Apoptosis in Cancer Therapy.- Structures of TNF Receptors and Their Interactions With Ligands.- Death Receptor Signaling in Embryonic Ectodermal Development.- Adaptor Proteins in Death Receptor Signaling.- Caspase Activation by the Extrinsic Pathway.- Death Signaling and Therapeutic Applications of TRAIL.- Death Receptor Mutations.- Regulation of Death Receptors.- Regulation of Trail Receptor Expression in Human Melanoma.- Regulation of Death Receptors by Synthetic Retinoids.- Role of p53 in Regulation of Death Receptors.- Proapoptotic Gene Silencing Via Methylation in Human Tumors.- Regulation of Death Receptor-Induced Apoptosis by NF-?B and Interferon Signaling Pathways.- TRAIL in Cancer Therapy.- Expression and Regulation of Death Receptors in Multiple Myeloma and Prostate Carcinoma.- Regulation of TRAIL-Induced Apoptosis by Transcriptional Factors.- Sensitizing Tumor Cells by Targeting Death Receptor Signaling Inhibitors.- Ceramide, Ceramidase, and FasL Gene Therapy in Prostate Cancer.- Gene Therapy Targeting Receptor-Mediated Cell Death to Cancers.- Combination of Chemotherapy and Death Ligands in Cancer Therapy.

Info autore

Wafik S. El-Deiry, M.D., Ph.D, is Professor of Medicine, Chief, Hematology/Oncology, Rose Dunlap Division Chair in Hematology/Oncology, and Associate Director for Translational Researchat Penn State Hershey Cancer Institute. Dr. El-Deiry is a well-respected and notable figure among cancer researchers, scientists, and clinicians. He has published almost 300 papers in his career and has over 29,000 totol citations, with an excellent h-index of 70.

Riassunto

An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes. The authors focus on the extrinsic system of death receptors, their regulation and function, and their abnormalities in cancer. Topics of particular interest include resistance to apoptosis, TRAIL signaling, death receptors in embryonic development, mechanisms of caspase activation, and death receptor mutations in cancer. Additional chapters address death signaling in melanoma, synthetic retinoids and death receptors, the role of p53 in death receptor regulation, immune suppression of cancer, and combination therapy with death ligands.

Testo aggiuntivo

From the reviews:

"The book is resourceful for both basic scientists and clinicians, who are interested in developing targeted therapies for cancer. … the book is a valuable tool for researchers as well as to those of us involved in teaching apoptosis to undergraduate and graduate students." (Harikrishna Nakshatri, Leukemia Research, 2005)

Relazione

From the reviews:

"The book is resourceful for both basic scientists and clinicians, who are interested in developing targeted therapies for cancer. ... the book is a valuable tool for researchers as well as to those of us involved in teaching apoptosis to undergraduate and graduate students." (Harikrishna Nakshatri, Leukemia Research, 2005)

Dettagli sul prodotto

Con la collaborazione di Wafik S. El-Deiry (Editore)
Editore Springer, Berlin
 
Lingue Inglese
Formato Copertina rigida
Pubblicazione 25.01.2013
 
EAN 9781588291721
ISBN 978-1-58829-172-1
Pagine 374
Dimensioni 191 mm x 265 mm x 26 mm
Peso 1960 g
Illustrazioni XII, 374 p.
Serie Cancer Drug Discovery and Development
Cancer Drug Discovery & Develo
Cancer Drug Discovery & Develo
Cancer Drug Discovery and Development
Categorie Scienze naturali, medicina, informatica, tecnica > Medicina > Branche cliniche

Tumor, C, Medicine, Oncology, Interferon, melanoma, Gene Therapy, Cell Death, prostate cancer

Recensioni dei clienti

Per questo articolo non c'è ancora nessuna recensione. Scrivi la prima recensione e aiuta gli altri utenti a scegliere.

Scrivi una recensione

Top o flop? Scrivi la tua recensione.

Per i messaggi a CeDe.ch si prega di utilizzare il modulo di contatto.

I campi contrassegnati da * sono obbligatori.

Inviando questo modulo si accetta la nostra dichiarazione protezione dati.